 Lineage Cell Therapeutics NYSEAMERICAN:LCTX was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the ... 